Amiodarone versus sotalol for atrial fibrillation.

By Bramahn . Singh, Steven N. Singh, D. Reda, X. C. Tang, B. Lopez, C. Harris, R. Fletcher, Satish C. Sharma, J. Atwood, A. Jacobson and 3 more. New England Journal of Medicine, 2005

640 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/4245058ec8b14520ae498d86d5d2a72fb271cf3f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Gerhard Hindricks
2. Gregory Y. H. Lip
3. A. Goette
4. Paulus Kirchhof
5. Ulrich Schotten

Citations in the corpus

• 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “(amiodarone: a few weeks) to promote pharmacological conversion and to achieve effective drug levels.(584,601)”
• Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. (2010, background): “In patients with paroxysmal or short-duration persistent AF who have had limited prior drug exposure, 20% to 40% of patients treated with class I drugs or sotalol and 60% to 70% of patients treated with amiodarone have no recurrence of AF at 1 year.(9-11) However, failure of prior ADT (due to either”
• ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ (2006, positive): “Information about the effects of antiarrhythmic and chronotropic therapies on quality of life is inconsistent (116,130,131).”
• ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit (2006, neutral): “Information about the effects of antiarrhythmic and chronotropic therapies on quality of life is inconsistent.(116,130,131) Neither the AFFIRM,(132) RACE,(124) PIAF (Pharmacologic Intervention in Atrial Fibrillation),(125) nor STAF (Strategies of Treatment of Atrial Fibrillation)(126) studies found ”
• Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). (2010, background): “53).(46) Drug-induced proarrhythmia with sotalol is due to excessive prolongation of the QT interval(115) and/ or bradycardia.”